<DOC>
	<DOCNO>NCT00226590</DOCNO>
	<brief_summary>This single institution Phase II study patient unresectable Stage IIIA IIIB non-small cell lung cancer . The treatment start 2 cycle gemcitabine carboplatin follow concurrent chemotherapy radiation . The chemoradiation include use paclitaxel carboplatin daily thoracic radiation total dose 74 Gy . Response rate determine follow chemotherapy gemcitabine carboplatin evaluate chemoradiation . Treatment toxicity also assess .</brief_summary>
	<brief_title>Induction Gemcitabine &amp; Carboplatin Followed Paclitaxel &amp; Carboplatin +XRT NSCLC</brief_title>
	<detailed_description>In trial adopt approach use induction concurrent chemotherapy together Thoracic Radiation Therapy ( TRT ) plan conformally tumor dose 74 Gy . Substitution gemcitabine paclitaxel induction chemotherapy allow u evaluate impact RRM1 expression activity agent . The expression Ribonucleotide Reductase , M1 Subunit ( RRM1 ) evaluate prior initiation therapy , follow induction chemotherapy prior concurrent chemoradiation , follow completion therapy CT-guided core needle biopsy . This single institution phase II clinical trial , induction treatment gemcitabine carboplatin follow concurrent chemoradiation use paclitaxel carboplatin daily thoracic radiation total dose 74 Gy patient unresectable Stage IIIA IIIB NSCLC . The specific clinical objective study follow : To determine response rate ( CT scan PET scan assessment ) two cycle induction chemotherapy gemcitabine carboplatin ; To determine response rate ( CT scan PET scan assessment ) concurrent thoracic radiation weekly paclitaxel carboplatin ; To evaluate pattern local distant failure patient treat induction chemotherapy follow concurrent chemoradiation accord regimen ; To estimate median , 1 year , overall survival ; To assess acute long term toxicity treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Eligibility Criteria : Histologically confirm unresectable nonsmall cell carcinoma lung ( adenocarcinoma , squamous cell carcinoma anaplastic large cell carcinoma ) . See TNM eligibility . Mediastinoscopy thoracoscopy patient mediastinal lymph node enlargement &lt; 2 cm CT scan suspicious PET scan confirm suspect involvement . These stag procedure mandatory patient obvious nodal involvement ( 2.0 cm great ) . Staging system : The New International Staging System lung cancer ( Clifton F. Mountain , 1997 ) follow . The following stage eligible : Patients stage IIIa disease eligible felt candidate possible resection follow neoadjuvant therapy ( unresectable T3N1 T13 primary tumor metastasis limit single station ipsilateral mediastinal lymph node ) . Patients stage IIIb disease without significant* pleural effusion eligible . This include patient metastases contralateral mediastinal supraclavicular node . Patients without significant pleural effusion constitute 1 ) see CT scan 2 ) reaccumulate one thoracentesis cytologically negative . No evidence distant metastasis . Patients must measurable disease Recist Evaluation Criteria Solid Tumors ( RECIST ) criterion . Baseline measurements/evaluations must obtain within 4 week prior registration . Patients must small cell carcinoma part histological specimen ( World Health Organization [ WHO ] classification 22.40 ) Performance status Eastern Cooperative Oncology Group ( ECOG ) 0 1 time registration . Patients preexist clinically significant peripheral neuropathy ineligible . Weight loss â‰¤ 5 % precede three month No prior systemic chemotherapy thoracic radiotherapy . Patients must adequate bone marrow reserve determine follow laboratory value : Obtained within 14 day prior registration . White blood cell count 4000/ul great granulocyte count 1500/ul great Platelet count 100,000/ul great Hemoglobin 10 gms/dl great . Adequate renal liver function determine follow laboratory value : Obtained within 14 day prior registration . Serum creatinine &lt; 1.5 mg/dl creatinine clearance great 50 cc/min Bilirubin le 1.5 mg/dl SGOT le 1.5 time normal No history prior concomitant malignancy past five year except surgically cure basal cell carcinoma skin carcinoma situ cervix . No concomitant life threaten uncontrolled serious medical illness cardiac arrhythmia , end stage congestive heart failure , liver disease significant hepatic insufficiency , organic brain syndrome . Women childbearing potential sexually active male strongly advise use accept effective method contraception . Age great equal 18 year Written , informed consent must obtain prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>carcinoma</keyword>
	<keyword>unresectable</keyword>
	<keyword>Stage IIIA</keyword>
	<keyword>Stage IIIB</keyword>
	<keyword>thoracic radiation</keyword>
</DOC>